Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront for the Non-opioid Neuropathic Pain Treatment, NRD.E1, for Greater China and Singapore
21.7.2022 10:58:00 EEST | Business Wire | Press release
Novaremed AG and NeuroFront Therapeutics (Hong Kong) Limited jointly announce the signing of an exclusive collaboration and commercialization agreement for Novaremed’s innovative non-opioid investigational drug, NRD.E1, being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications. Under the terms of the agreement, Novaremed is eligible to receive from NeuroFront over USD 130 million in option and exercise fees as well as development, regulatory and sales milestone payments plus royalties on net sales.
Under the terms of the agreement, Novaremed will grant NeuroFront an exclusive option to obtain exclusive development, commercialization and manufacturing rights to NRD.E1, Novaremed’s first-in-class, innovative non-opioid investigational drug candidate for the treatment of neuropathic pain. The agreement allows NeuroFront to develop and commercialize NRD.E1 as treatment of painful diabetic peripheral neuropathy (PDPN) and any other neuropathic pain indications in the Greater China territory (including Mainland China, Hong Kong, Macau, and Taiwan) and Singapore.
NeuroFront has the right to exercise its license option at its discretion, but no later than upon completion of the Phase 2b trial of NRD.E1 in PDPN, which will start patient enrollment in coming weeks.
In case NeuroFront successfully develops and registers NRD.E1 in additional neuropathic pain indications in the licensed territory, Novaremed is also eligible to receive additional development and regulatory milestone payments for each additional indication.
“We are very delighted collaborating with NeuroFront to advance our non-opioid neuropathic pain treatment for patients suffering from PDPN and other neuropathic pain indications in China. Currently, approved medications for PDPN provide inadequate pain relief and are associated with many intolerable side effects. Based on both preclinical and clinical data, we believe NRD.E1 has the potential to offer unique benefits and revolutionize the way PDPN is treated,” said Isaac Kobrin, MD, Executive Chairman of Novaremed. “NeuroFront’s development and commercial expertise and its focus on innovative CNS drugs is complementary to our expertise and an ideal fit for Novaremed.”
“There are up to 19 million patients suffering from PDPN in China, but no new innovative drug has been introduced in the market for more than 15 years. There exists a significant unmet medical need and hence a great opportunity for NRD.E1, a first-in-class, novel treatment that has already demonstrated clinical effectiveness in a Phase 2a clinical trial and subsequently received US FDA Fast Track Designation and NIH sponsorship for its Phase 2b trial,” said June Yan, CEO of NeuroFront. “NeuroFront is very excited to partner with Novaremed to change the lives of many PDPN patients in Greater China and Singapore.”
This partnership and the transaction were facilitated with the assistance of Cukierman and Company Investment House.
About NRD.E1 and the treatment of chronic pain
NRD.E1 is an orally active small molecule with a novel mechanism of action by modulating Lyn kinase and has patent protection until 2040. NRD.E1 is Novaremed’s lead drug candidate currently being developed to treat painful diabetic peripheral neuropathy (PDPN). Novaremed successfully completed three Phase 1 studies [1] and one double-blind, placebo-controlled Phase 2a dose-finding proof-of-concept study [2] in which NRD.E1 showed a clinically relevant reduction in patient-reported pain (measured as an improvement in mean neuropathic pain score) and was very well tolerated at all doses tested.
On the basis of these results, NRD.E1 has been granted Fast Track Designation by the US FDA and was selected by the National Institutes of Health (NIH) in the US as the only oral agent to be included in the NIH-HEAL (Help End Long-term Addiction) program. The NIH will sponsor and execute a 12-week, double-blind, placebo-controlled Phase 2b study in patients with moderate to severe PDPN in the US. Recruitment into this clinical trial will start in coming weeks.
About NeuroFront
NeuroFront is a China-based clinical stage neuroscience biotech company with a focus on developing and commercializing innovative neuroscience therapies to address unmet needs and improve patients' lives in China and Asia. NeuroFront was established by top-tier life sciences investors, including Nan Fung Life Sciences and Pivotal bioVenture Partners China, and is led by an elite team of neuroscience industry veterans with substantial and compelling expertise in China and globally in both R&D and the commercialization of CNS products. NeuroFront is building a portfolio of innovative, transformative CNS therapies that treat migraine, painful diabetic peripheral neuropathy, depression, ADHD, and other CNS diseases with high unmet medical needs. For more information: www.neurofrontrx.com.
About Novaremed
Novaremed AG, a privately held clinical-stage biopharmaceutical company, is developing a pipeline of innovative medications for chronic pain management to address the high unmet medical need for better pain relief and as an alternative to opioids. Its lead product is NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action, has FDA Fast Track Designation and IND-approval to proceed with a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy (PDPN). The earlier stage pipeline addressing chronic neuropathic pain includes the development candidates MP-101 (Phase 2 stage), and MP-103 (preclinical stage), targeting the unmet medical need of prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN). Novaremed Ltd (Israel) and Metys Pharmaceuticals AG (Switzerland) are fully owned subsidiaries of Novaremed AG, domiciled in Basel (Switzerland). For more information: www.novaremed.com.
References
[1] Tiecke E., Rainisio M., Guentert T., Müller S., Hochman L., Kaplan E., Mangialaio S. (2022). First-in-human single-ascending-dose, multiple-dose and food interaction studies of NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy. Clinical Pharmacology in Drug Development (CPDD). (https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1103)
[2] Tiecke E., Rainisio M., Eisenberg E., Wainstein J., Kaplan E., Silverberg M., Hochman L., Mangialaio S. (2022). NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy – a randomized proof of concept study. European Journal of Pain. (https://onlinelibrary.wiley.com/doi/10.1002/ejp.1989)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005391/en/
Contact information
Contact for Novaremed
Mark Altmeyer, Executive Member of the Board
mark.altmeyer@novaremed.com
Contact for NeuroFront
Bin Yao, VP of Operations and Commercialization
bin.yao@neurofrontrx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Brings Direct-to-Consumer Commerce Expertise to Gamesforum Hamburg 2026 With Keynote and Panel Appearances9.6.2026 15:01:00 EEST | Press release
Xsolla, a global leader in video game commerce, today announced its participation in Gamesforum Hamburg 2026, taking place June 9–10, 2026, at NORD EVENT Panoramadeck in Hamburg, Germany. As an Exclusive Global Partner of the Gamesforum series, Xsolla will bring its direct-to-consumer commerce expertise to one of Europe's leading gatherings for mobile game growth and monetization, with Jane Startseva, Vice President of Business Development, EMEA, taking the stage across two sessions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609166526/en/ Graphic: Xsolla Xsolla's presence in Hamburg underscores its role at the center of gaming's shift toward direct-to-consumer commerce: On June 9 at 10:00 AM, Jane joined Adam Smart, Global Director of Product – Gaming at AppsFlyer, for a 30-minute keynote titled "Web Shops and Attribution: Closing the Revenue Gap." As web shops cement their role as a primary monetization channel for
Duetti Expands Funding Offerings for Independent Artists With Two New Programs9.6.2026 15:01:00 EEST | Press release
Duetti Inc. (“Duetti” or the “Company”), the music company that partners with independent artists and songwriters to buy, manage, and market their catalogs, announces today a significant expansion of its funding offering. Artists can now sell their master recording tracks, or parts thereof, in as little as six months after release - substantially earlier than the company’s prior two-year threshold. Duetti is also launching its new Remix Program, which allows independent artists to create remixes, covers, and other derivative works from Duetti’s 30,000-track catalog (across both masters and compositions). In return, artists can receive upfront cash compensation, ongoing royalty % share, 0% distribution fees, and dedicated marketing support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609063445/en/ UNLOCKING VALUE, EARLIER THAN EVER Duetti is leveraging its proprietary AI-driven predictive models to materially lower the
The Open Group Releases OSDU® Data Platform Standard, Version 1.09.6.2026 15:00:00 EEST | Press release
The Open Group, the global vendor‑neutral technology consortium, today announced the release of the OSDU® Data Platform Standard, Version 1.0. The new standard establishes a stable, clearly defined baseline for data platform capabilities, supporting greater interoperability, consistency, and confidence across the energy industry. The OSDU Data Platform Standard, Version 1.0 is designed to help organizations better manage, access, and use enterprise data by reducing fragmentation and breaking down data silos. It provides a common framework for organizing and accessing data securely and efficiently, supporting improved collaboration, innovation, and decision‑making. Key benefits of the standard include interoperability by design, increased stability for application development and deployment, and a clear foundation for certification. Operators benefit from greater choice and reduced integration effort, independent software vendors can develop against a defined standard, and platform prov
Clearlake Completes Strategic Acquisition of Pathway Capital Management9.6.2026 15:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced the completion of its acquisition of Pathway Capital Management (“Pathway”), a global provider of private market solutions for institutional and wealth markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609839186/en/ The strategic acquisition significantly expands Clearlake’s private markets platform, adding complementary capabilities and reinforcing its position as a leading diversified alternative asset manager. Founded in 1991, Pathway manages more than $95 billion in assets and brings a proven track record across private equity, private credit, infrastructure, secondaries and co-investments through customized private markets programs and multi-investor funds. The combination will bolster Clearlake’s priva
Watchmaker to Unveil New Technologies Addressing NGS Workflow Bottlenecks and Sequencing Accuracy Challenges at ESHG 20269.6.2026 15:00:00 EEST | Press release
Watchmaker Genomics, a leader in high-performance NGS workflow solutions, today announced it will unveil two new technologies at the European Society of Human Genetics (ESHG) 2026 conference, designed to address persistent bottlenecks in sequencing workflow scalability and amplification accuracy. The launches include the EquiPlex™ Normalization Kit, which simplifies library normalization using a novel Cas9-based approach, and Equinox® Prime Library Amplification Master Mix, engineered to improve indel accuracy in repetitive genomic regions while delivering superior amplification performance across sequencing applications. Built on Watchmaker’s expertise in protein engineering and integrated workflow design, the technologies reflect the company’s continued focus on solving real-world sequencing challenges that impact operational efficiency, scalability, and downstream data quality. “Sequencing workflows continue to grow in scale and complexity, but many of the core bottlenecks researche
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom